Related Experiment Video
Updated: Apr 14, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects
1Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts.
Abstract:
The crystal structure of RAS was first solved 25 years ago. In spite of tremendous and sustained efforts, there are still no drugs in the clinic that directly target this major driver of human cancers. Recent success in the discovery of compounds that bind RAS and inhibit signaling has fueled renewed enthusiasm, and in-depth understanding of the structure and function of RAS has opened new avenues for direct targeting. To succeed, we must focus on the molecular details of the RAS structure and understand at a high-resolution level how the oncogenic mutants impair function. Structural networks of intramolecular communication between the RAS active site and membrane-interacting regions on the G-domain are disrupted in oncogenic mutants. Although conserved across the isoforms, these networks are near hot spots of protein-ligand interactions with amino acid composition that varies among RAS proteins. These differences could have an effect on stabilization of conformational states of interest in attenuating signaling through RAS. The development of strategies to target these novel sites will add a fresh direction in the quest to conquer RAS-driven cancers. Clin Cancer Res; 21(8); 1810-8. ©2015 AACR. See all articles in this CCR Focus section, "Targeting RAS-Driven Cancers."
Insights
Targeting RAS proteins, key drivers of cancer, remains challenging. New research reveals how oncogenic mutations disrupt structural networks, offering novel strategies for developing cancer drugs.
Area of Science:
- Oncology
- Molecular Biology
- Structural Biology
Background:
- RAS proteins are critical drivers of human cancers, yet direct targeting drugs are unavailable despite decades of research.
- Recent advances in understanding RAS structure and function offer new opportunities for therapeutic intervention.
- Overcoming challenges in RAS-targeted therapy requires a high-resolution understanding of oncogenic mutations.
Discussion:
- Oncogenic RAS mutants disrupt intramolecular communication networks between the active site and membrane-binding regions.
- These disrupted networks involve conserved structural elements but exhibit isoform-specific amino acid variations.
- Such variations may influence the stabilization of signaling-attenuating conformational states.
Key Insights:
- Structural networks critical for RAS signaling are altered in oncogenic mutants.
- Isoform-specific differences in these networks present potential targets for selective drug development.
- Understanding these molecular details is crucial for designing effective RAS-targeted therapies.
Outlook:
- Developing strategies to target novel sites within RAS structural networks offers a promising new direction.
- Conquering RAS-driven cancers may be achievable through innovative therapeutic approaches.
- Further research into RAS structural dynamics and mutant functions is essential.
More Related Videos
Related Concept Videos
The Ras Gene
Ras is a...
The Ras Gene
Spontaneous and Induced Mutations
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Mutations in Microorganisms
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...

